New treatments for hyperkalaemia: clinical use in cardiology

Area of Science:

• Nephrology and Cardiology
• Pharmacology of novel potassium binders

Background:

• Hyperkalemia presents a significant health burden, with even mild cases linked to increased morbidity and mortality.
• Patients with chronic conditions like heart failure, hypertension, chronic kidney disease, and diabetes are particularly vulnerable to hyperkalemia.
• Traditional hyperkalemia management primarily relied on short-term methods, lacking safe and effective long-term therapeutic options.

Purpose of the Study:

• To review novel potassium binders, patiromer and sodium zirconium cyclosilicate, for hyperkalemia management.
• To discuss the clinical implications of these new agents, particularly in patients with chronic cardiovascular conditions.

Main Methods:

• Review of recently approved therapies for hyperkalemia.
• Focus on patiromer and sodium zirconium cyclosilicate.
• Analysis of clinical implications for patients with chronic cardiovascular diseases.

Main Results:

• Two novel potassium binders, patiromer and sodium zirconium cyclosilicate, have received FDA approval.
• These agents offer safe, efficacious, and well-tolerated options for long-term hyperkalemia management.
• Significant clinical implications are noted for managing hyperkalemia in patients with chronic cardiovascular conditions.

Conclusions:

• Patiromer and sodium zirconium cyclosilicate represent a significant advancement in hyperkalemia treatment.
• These novel binders provide crucial long-term management solutions, addressing a previously unmet clinical need.
• Their use is particularly relevant for patients with comorbid chronic diseases, improving cardiovascular health outcomes.